Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated a positive growth trajectory in its EsoGuard testing, with a sequential increase in the number of tests processed from 2,756 in Q2 to 2,841 in Q3, highlighting increasing market demand for its diagnostic services. The company's valuation is seen as attractive, as it appropriately reflects a balance of inherent risks while indicating substantial upside potential, further supported by an upward revision in the 12-month price target based on net present value analysis. Additionally, the anticipated growth of its newly commercialized products is expected to significantly contribute to revenues in 2025 and 2026, enhancing the overall positive financial outlook for PAVmed.

Bears say

PAVmed Inc. reported a pro forma net loss of $0.8 million for the latest quarter, indicating a continued struggle with profitability as it fell short of both its own and consensus earnings estimates. The decline in the number of EsoGuard tests processed, which decreased to 2,756 from 3,034 in the previous quarter, highlights potential challenges in demand for its diagnostic services. Additionally, the company faces numerous risks including liquidity concerns, regulatory hurdles, and market competition, which collectively contribute to a negative outlook on its financial performance and future growth prospects.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.